Research programme: cancer therapeutics - Bioncotech TherapeuticsAlternative Names: BO-011; BO-110
Latest Information Update: 13 Jan 2014
At a glance
- Originator Bioncotech Therapeutics
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; Ephrin-B2 antagonists; IFIH1 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Jan 2014 Preclinical trials in Cancer in Spain (unspecified route) prior to January 2014